CTMX — CytomX Therapeutics, Inc. stock price, charts and financials

QT43CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.44
-0.02-0.58%
OverviewShort InterestFilings
CTMXQT43CytomX Therapeutics, Inc.·NASDAQ
3.44-0.58%

Latest SEC Filings

Form category
Filing Date ▾FormDescriptionFilingDocument
Aug 07, 2026SC 13GBeneficial ownership statement (passive)
Aug 06, 20268-KCurrent report
Aug 06, 202610-QQuarterly report
Aug 06, 2026S-8Registration of employee benefit securities
Aug 05, 20263Initial statement of beneficial ownership
Aug 05, 20264Statement of changes in beneficial ownership
Aug 03, 2026SC 13GBeneficial ownership statement (passive)
Jul 30, 20263Initial statement of beneficial ownership
Jul 30, 20264Statement of changes in beneficial ownership
Jul 27, 20268-KCurrent report
Jul 27, 2026SC 13GBeneficial ownership statement (passive)
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20268-KCurrent report
Jun 17, 20264Statement of changes in beneficial ownership
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
#1 / 25 of 315
Page
▼
/ 13